Stockreport

Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF – Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial ––  CONTACT-02 is the second of three phase 3 pivotal trials that are part of a clinical [Read more]